A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

NCT05338957 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Miracogen Inc.